India, Oct. 9 -- Sagimet Biosciences Inc. (SGMT) announced positive 52-week results from a Phase 3 open-label extension study of denifanstat in patients with moderate-to-severe acne vulgaris. The data, generated by its license partner Ascletis BioScience in China, will be presented at the 2026 Fall Clinical Dermatology Conference.
The ASC40-304 study evaluated the long-term safety and efficacy of denifanstat, an investigational once-daily oral fatty acid synthase (FASN) inhibitor. A total of 240 patients who completed the preceding 12-week Phase 3 ASC40-303 trial entered the extension study.
After up to 52 weeks of treatment, patients showed continued improvements across efficacy measures. Results included a 57% Investigator's Global Asse...